Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547469 | 0.84 | GABRA1 (0.66) | GABRA1GABRB2MAPTKMT2AGAA | |
| SCHEMBL8665741 | 0.81 | LMNA (0.41) | GABRA1GABRB2MAPTKMT2AGAA | |
| Formaldehyde SCHEMBL28004393 | 0.81 | GABRA1 (0.61) | GABRA1GABRB2MAPTKMT2AGAA | |
| SCHEMBL1897113 | 0.80 | ERN1 (0.47) | ALOX12ALDH1A1HPGDALOX15ERN1 | |
| SCHEMBL5451047 | 0.80 | LMNA (0.43) | GABRA1GABRB2MAPTKMT2AGAA | |
| SCHEMBL11223610 | 0.79 | LMNA (0.40) | GABRA1GABRB2MAPTKMT2AGAA | |
| SCHEMBL69697 | 0.79 | TYR (0.58) | GABRA1GABRB2MAPTKMT2AGAA | |
| SCHEMBL1006107 | 0.78 | XDH (0.70) | GABRA1GABRB2MAPTKMT2AGAA | |
| SCHEMBL8259600 | 0.78 | GABRA1 (0.52) | GABRA1GABRB2MAPTKMT2AGAA | |
| SCHEMBL4573203 | 0.77 | ALOX15 (0.38) | MAPTKMT2AGAALMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647678-B2 | Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-12 | — | — | US | disclosed |
| US-10647678-B2 | Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-12 | — | — | US | disclosed |
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| EP-3283484-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-21 | — | — | EP | disclosed |
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2885285-B1 | PYRAZOLE DRIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2016-10-19 | — | — | EP | disclosed |
| WO-2016156872-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016156872-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-06 | — | — | WO | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1847535-A1 | 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1847535-A1 | 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007030150-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |
| EP-0560554-A2 | Antitumor compositions and methods of treatment | ELI LILLY AND COMPANY (US) | 1993-09-15 | — | — | EP | disclosed |
| US-5169860-A | Benzofuran or benzothiophene arylsulfonylureas | ELI LILLY AND COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | HSF1, HSP90AB1, HSP90AB2P | GABRA1 4521/4885GABRB2 4220/4885MAPT 2433/4885 |
| US-10647678-B2 | Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity | HSF1, HSP90AB1, HSP90AB2P | GABRA1 4521/4885GABRB2 4220/4885MAPT 2433/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | GABRA1 123/4885GABRB2 184/4885MAPT 2152/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | GABRA1 243/4885GABRB2 279/4885MAPT 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.